Endocyte Inc. (ECYT) Drops 5.68% on January 27

Equities Staff |

Endocyte Inc. (ECYT) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 5.68% to $3.32, a loss of $-0.2 per share. Starting at an opening price of $3.52 a share, the stock traded between $3.30 and $3.52 over the course of the trading day. Volume was 207,160 shares over 1,011 trades, against an average daily volume of 278,234 shares and a total float of 41.98 million.

The losses send Endocyte Inc. down to a market cap of $139.36 million. In the last year, Endocyte Inc. has traded between $6.76 and $2.65, and its 50-day SMA is currently $4.04 and 200-day SMA is $5.09.

Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.

Endocyte Inc. is based out of West Lafayette, IN and has some 81 employees. Its CEO is P. Ellis.

For a complete fundamental analysis analysis of Endocyte Inc., check out Equities.com’s Stock Valuation Analysis report for ECYT. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets

D-Wave

D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…